Breaking News

Zillow Buys Trulia for $3.5 Billion in Stock
Tweet TWEET

Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F

      Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F

PR Newswire

NANJING, China, April 27, 2013

NANJING, China, April 27, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group
("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company
specializing in the development, manufacturing, and marketing of branded and
proprietary pharmaceuticals in China, announced today that the Company filed
its annual report on Form 20-F for the year ended December 31, 2012 with the
Securities and Exchange Commission on April 26, 2013, U.S. Eastern Time. The
annual report can be accessed on the Company's investor relations website at
http://ir.simcere.com. The Company will provide a hard copy of the annual
report containing its audited financial statements for the year ended December
31, 2012, free of charge, to its shareholders and ADS holders upon request.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group ("Simcere") (NYSE: SCR) is a leading
pharmaceutical company specializing in the development, manufacturing, and
marketing of branded and proprietary pharmaceuticals in China. Simcere
concentrates its research and development efforts on the treatment of diseases
with high incidence and/or mortality rates and for which there is a clear
demand for more effective pharmacotherapy such as cancer, strokes,
cardiovascular disease, infectious diseases and pain. For more information
about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:

Email: ir@simcere.com

In Nanjing:
                             In the United States:
Jie Liu D'Elia
                             Cindy Zheng
Vice President
                             Brunswick Group LLC
Simcere Pharmaceutical Group
                             Tel: 1-212-333-3810
Tel: 86-25-8556-6666*8857
In Beijing:

Yue Yu

Brunswick Group

Tel: 86-10-5960-8600

SOURCE Simcere Pharmaceutical Group

Website: http://www.simcere.com
Website: http://ir.simcere.com